Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

ALK's Acarizax (12 SQ-HDM SLIT) accepted by SMC for moderate-to-severe house dust mite allergic rhinitis in Scotland
Protein therapy, autoimmune, allergen immunotherapy, sublingual immunotherapy, allergic rhinitis, house dust mite allergy - Read more

Akeso's ivonescimab wins China Ph3-backed approval for first-line squamous non-small-cell lung cancer
Antibody, cancer, bispecific antibody, non-small cell lung cancer, PD-1/VEGF, first-line therapy - Read more

PTC Therapeutics acquires Sangamo Therapeutics' Fabry gene therapy for $111M upfront, $100M milestones
Acquisition, rare disease, gene therapy, milestone payments, regulatory - Read more

Zealand Pharma sells rusfertide milestone, royalty rights to Royalty Pharma for up to $100M
Royalty purchase, rare disease, small molecule, milestone payments, royalties - Read more

Allist Pharmaceuticals in-licenses ArriVent BioPharma's MUC16/NaPi2b dual-targeting ADC AST12608/ARR-002 for Greater China
Licensing deal, oncology, antibody-drug conjugate, manufacturing, commercialization - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Taiho Pharmaceutical, Cullinan Therapeutics' (zipalertinib) EGFR inhibitor meets Ph3 primary endpoint in first-line non-small cell lung cancer
Small molecule, cancer, EGFR inhibitor, non-small cell lung cancer, EGFR exon 20 insertion, combination therapy - Read more

Khartis Therapeutics emerges with $95M to advance an oral thyroid eye disease therapy into clinical trials
Ophthalmology, small molecule, autoimmune, IGF-1R, preclinical - Read more

NeXell Bio emerges from stealth with AI-driven CAR-T platform targeting solid tumors
CAR-T, oncology, operational, strategic - Read more

Legend Biotech posts first profitable quarter amid leadership transition and rising Carvykti competition
CAR-T, oncology, financial, competitive, operational - Read more

Beyang Therapeutics raises ~$30M Series A to advance AI-designed drug platform
AI/ML platform, drug discovery, small molecule, preclinical, platform-enabled - Read more

Remepy raises $36M Series A to advance Parkinson's hybrid drug toward Phase III
Neurological, Parkinson's disease, AI/ML platform, hybrid drug, clinical-stage - Read more

Amplifica raises $26M Series B to advance injectable pipeline for hair growth
Clinical-stage, hair loss, injectable, small molecule, platform technology - Read more

AbCellera Biologics plans $200M public offering to advance internal pipeline, including ABCL635
Antibody, drug discovery, clinical-stage, platform technology - Read more

Outlook Therapeutics prices $55M public offering of common stock and warrants, advancing LYTENAVA commercial launch
Ophthalmology, small molecule, clinical-stage, commercialization - Read more

Amgen to open science and innovation center at Genome Valley in Hyderabad, operational by 2027
R&D expansion, drug discovery, operational, strategic - Read more

Alfasigma to acquire Nordic Pharma from Sever Life Sciences, expanding into Japan, Canada markets
Small molecule, autoimmune, strategic, major transaction - Read more

Earth Science Tech acquires Meduvo LLC, expanding compounding pharmacy network to 34 U.S. jurisdictions
Compounding pharmacy, strategic, major transaction, operational - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Neurocrine Biosciences' Prader-Willi drug Vykat linked to seven deaths, raising safety concerns
Small molecule, rare disease, regulatory, competitive - Read more

PDS Biotechnology halts phase 3 head and neck cancer trial to prioritize colorectal cancer candidate PDS0301
Immunotherapy, oncology, strategic, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here